سوق الأدوية المضادة للعدوى العالمية - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ANTI-INFECTIVE DRUGS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL ANTI-INFECTIVE DRUGS MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL ANTI-INFECTIVE DRUGS MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S 5 FORCES MODEL

6 INDUSTRY INSIGHTS

7 EPIDEMIOLOGY

7.1 DISEASE PREVALENCE BY COUNTRY

7.2 DISEASE INCIDENCE BY COUNTRY

7.3 RISK FACTORS

(FACTORS THAT INCREASE THE LIKELIHOOD OF DEVELOPING A DISEASE, SUCH AS AGE, GENDER, LIFESTYLE FACTORS, ENVIRONMENTAL EXPOSURES, AND GENETIC PREDISPOSITION)

7.4 HEALTHCARE UTILIZATION

(HOW THE DISEASE AFFECTS HEALTHCARE UTILIZATION, SUCH AS HOSPITALIZATIONS, EMERGENCY ROOM VISITS, AND OUTPATIENT VISITS)

8 REGULATORY FRAMEWORK

8.1 REGULATORY APPROVAL PROCESS

8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

8.3 REGULATORY APPROVAL PATHWAYS

8.4 LICENSING AND REGISTRATION

8.5 POST-MARKETING SURVEILLANCE

8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIAL STATUS

9.1.1 CANDIDATE/AGENT

9.1.2 PROPERTIES

9.1.3 COMPANY NAME

9.1.4 THERAPEUTIC AREA

9.1.5 PRODUCT NAME

9.1.6 GENERIC NAME

9.1.7 TYPE

9.1.8 RESEARCH CODE

9.1.9 INDICATION

9.1.10 ORIGINATOR

9.1.11 SPONSOR

9.1.12 COLLABORATOR

9.1.13 LICENSOR

9.1.14 LICENSEE

 

9.2 DISTRIBUTION OF PRODUCTS BY PHASE

9.2.1 PRECLINICAL/RESEARCH PROJECT

9.2.2 PHASE I

9.2.3 PHASE II

9.2.4 PHASE III

9.2.5 PHSE IV

9.3 NUMBER OF SUBJECTS IN CLINICAL TRIALS

9.3.1 PHASE I

9.3.2 PHASE II

9.3.3 PHASE III

9.4 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE

9.4.1 PRECLINICAL/RESEARCH PROJECT

9.4.2 PHASE I

9.4.3 PHASE II

9.4.4 PHASE III

9.4.5 PHASE IV

9.5 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE

9.5.1 PRECLINICAL/RESEARCH PROJECT

9.5.2 PHASE I

9.5.3 PHASE II

9.5.4 PHASE III

9.5.5 PHASE IV

9.6 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE

9.6.1 PRECLINICAL/RESEARCH PROJECT

9.6.2 PHASE I

9.6.3 PHASE II

9.6.4 PHASE III

9.6.5 PHASE IV

10 MARKETED DRUG ANALYSIS

10.1 DRUG

10.1.1 BRAND NAME

10.1.2 GENERICS NAME

10.2 THERAPEUTIC INDIACTION

10.3 PHARACOLOGICAL CLASS OD THE DRUG

10.4 DRUG PRIMARY INDICATION

10.5 MARKET STATUS

10.6 MEDICATION TYPE

10.7 DRUG DOSAGES FORM

10.8 DOSAGES AVAILABILITY

10.9 PACKAGING TYPE

10.1 DRUG ROUTE OF ADMINISTRATION

10.11 DOSING FREQUENCY

10.12 DRUG INSIGHT

AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

10.12.1 FORECAST MARKET OUTLOOK

10.12.2 CROSS COMPETITION

10.12.3 THERAPEUTIC PORTFOLIO

10.12.4 CURRENT DEVELOPMENT SCENARIO

11 MARKET ACCESS

11.1 10-YEAR MARKET FORECAST

11.2 CLINICAL TRIAL RECENT UPDATES

11.3 ANNUAL NEW FDA APPROVED DRUGS

11.4 DRUGS MANUFACTURER AND DEALS

11.5 MAJOR DRUG UPTAKE

11.6 CURRENT TREATMENT PRACTICES

11.7 IMPACT OF UPCOMING THERAPY

12 R & D ANALYSIS

12.1 COMPARATIVE ANALYSIS

12.2 DRUG DEVELOPMENTAL LANDSCAPE

12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

12.4 THERAPEUTIC ASSESSMENT

12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

13 PATENT ANALYSIS

13.1 PATENT LANDSCAPE

13.2 USPTO NUMBER

13.3 PATENT EXPIRY

13.3.1 US PATENT EXPIRY

13.3.2 EUROPE PATENT EXPIRY

13.4 EPIO NUMBER

13.5 PATENT STRENGTH AND QUALITY

13.6 PATENT CLAIMS

13.7 PATENT CITATIONS

13.8 PATENT LITIGATION AND LICENSING

13.9 FILE OF PATENT

 

13.1 PATENT RECEIVED CONTRIES

13.11 TECHNOLOGY BACKGROUND

14 COMPETITIVE INTELLIGENCE TRACKING DATA

14.1 CLINICAL TRIAL MONITORING ANALYSIS

14.2 REGULATORY AND COMMERCIAL MONITORING ANALYSIS

15 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY PRODUCT TYPE

(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS )

15.1 OVERVIEW

15.2 ANTIBIOTICS DRUGS

15.2.1 CEPHALOSPORINS

15.2.1.1. CEPHALEXIN

15.2.1.1.1. MARKET VALUE (USD MILLION)

15.2.1.1.2. MARKET VOLUME (UNITS)

15.2.1.1.3. AVERAGE SELLING PRICE (USD)

15.2.1.2. CEFTRIAXONE

15.2.1.3. CEFUROXIME

15.2.1.4. CEFTAZIDIME

15.2.1.5. CEFIXIME

15.2.1.6. OTHER

15.2.2 PENICILLIN

15.2.2.1. AMOXICILLIN

15.2.2.2. AMPICILLIN

15.2.2.3. PENICILLIN G

15.2.2.4. METHICILLIN

15.2.2.5. AUGMENTIN

15.2.2.6. OTHER

15.2.3 FLUOROQUINOLONES

15.2.3.1. CIPROFLOXACIN

15.2.3.2. LEVOFLOXACIN

15.2.3.3. MOXIFLOXACIN

15.2.3.4. NORFLOXACIN

15.2.3.5. OTHER

15.2.4 MACROLIDES

15.2.4.1. AZITHROMYCIN

15.2.4.2. CLARITHROMYCIN

15.2.4.3. ERYTHROMYCIN

15.2.4.4. OTHER

15.2.5 CARBAPENEM

15.2.5.1. IMIPENEM

15.2.5.2. MEROPENEM

15.2.5.3. DORIPENEM

15.2.5.4. OTHER

15.2.6 TETRACYCLINES

15.2.6.1. DOXYCYCLINE

15.2.6.2. TETRACYCLINE

15.2.6.3. MINOCYCLINE

15.2.6.4. OTHER

15.2.7 AMINOGLYCOSIDES

15.2.7.1. GENTAMICIN

15.2.7.2. TOBRAMYCIN

15.2.7.3. AMIKACIN

15.2.7.4. STREPTOMYCIN

15.2.7.5. OTHER

15.2.8 GLYCOPEPTIDES

15.2.8.1. VANCOMYCIN

15.2.8.2. TEICOPLANIN

15.2.8.3. OTHER

15.2.9 OXAZOLIDINONES

15.2.9.1. LINEZOLID

15.2.9.2. OTHER

15.2.10 SULFONAMIDES

15.2.10.1. TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX)

15.2.10.2. OTHER

15.2.11 OTHERS

15.2.11.1. CLINDAMYCIN

15.2.11.2. METRONIDAZOLE

15.2.11.3. NITROFURANTOIN

15.2.11.4. RIFAMPIN

15.2.11.5. OTHER

15.3 ANTIVIRALS DRUGS

15.3.1 NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)

15.3.1.1. LAMIVUDINE

15.3.1.2. ZIDOVUDINE

15.3.1.3. TENOFOVIR DISOPROXIL FUMARATE

15.3.1.4. EMTRICITABINE

15.3.1.5. ABACAVIR

15.3.1.6. OTHER

15.3.2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)

15.3.2.1. EFAVIRENZ

15.3.2.2. NEVIRAPINE

15.3.2.3. DELAVIRDINE

15.3.2.4. RILPIVIRINE

15.3.2.5. OTHER

15.3.3 PROTEASE INHIBITORS (PIS)

15.3.3.1. RITONAVIR

15.3.3.2. SAQUINAVIR

15.3.3.3. LOPINAVIR/RITONAVIR

15.3.3.4. ATAZANAVIR

15.3.3.5. DARUNAVIR

15.3.3.6. OTHER

15.3.4 INTEGRASE INHIBITORS

15.3.4.1. RALTEGRAVIR

15.3.4.2. DOLUTEGRAVIR

15.3.4.3. ELVITEGRAVIR

15.3.4.4. OTHER

15.3.5 FUSION INHIBITORS

15.3.5.1. ENFUVIRTIDE

15.3.5.2. IBALIZUMAB

15.3.5.3. OTHER

15.3.6 CCR5 ANTAGONISTS

15.3.6.1. MARAVIROC

15.3.6.2. OTHER

15.3.7 NEURAMINIDASE INHIBITORS

15.3.7.1. OSELTAMIVIR

15.3.7.2. ZANAMIVIR

15.3.7.3. PERAMIVIR

15.3.7.4. BALOXAVIR MARBOXIL

15.3.7.5. OTHER

15.3.8 POLYMERASE INHIBITORS (HCV)

15.3.8.1. SOFOSBUVIR

15.3.8.2. LEDIPASVIR-SOFOSBUVIR

15.3.8.3. GLECAPREVIR-PIBRENTASVIR

15.3.8.4. DACLATASVIR

15.3.8.5. OTHER

 

15.3.9 NEURAMINIDASE INHIBITORS (INFLUENZA)

15.3.9.1. OSELTAMIVIR

15.3.9.2. ZANAMIVIR

15.3.9.3. PERAMIVIR

15.3.9.4. BALOXAVIR MARBOXIL

15.3.9.5. OTHER

15.3.10 OTHER

15.4 ANTIFUNGAL

15.4.1 AZOLES

15.4.1.1. FLUCONAZOLE

15.4.1.2. ITRACONAZOLE

15.4.1.3. VORICONAZOLE

15.4.1.4. POSACONAZOLE

15.4.1.5. KETOCONAZOLE

15.4.1.6. OTHER

15.4.2 POLYENES

15.4.2.1. AMPHOTERICIN B

15.4.2.2. NYSTATIN

15.4.2.3. OTHER

15.4.3 ECHINOCANDINS

15.4.3.1. CASPOFUNGIN

15.4.3.2. MICAFUNGIN

15.4.3.3. ANIDULAFUNGIN

15.4.3.4. OTHER

15.4.4 ALLYLAMINES

15.4.4.1. TERBINAFINE

15.4.4.2. NAFTIFINE

15.4.4.3. OTHER

15.4.5 PYRIMIDINE ANALOGS

15.4.5.1. FLUCYTOSINE

15.4.5.2. GRISEOFULVIN

15.4.5.3. OTHER

15.4.6 TOPICAL ANTIFUNGALS

15.4.6.1. CLOTRIMAZOLE

15.4.6.2. MICONAZOLE

15.4.6.3. ECONAZOLE

15.4.6.4. KETOCONAZOLE

15.4.6.5. TERBINAFINE

15.4.6.6. OTHER

 

15.4.7 ANTIFUNGAL ANTIBIOTICS

15.4.7.1. NATAMYCIN

15.4.7.2. AMPHOTERICIN B

15.4.7.3. OTHER

15.4.8 TRIAZOLES

15.4.8.1. ISAVUCONAZOLE

15.4.8.2. RAVUCONAZOLE

15.4.8.3. ALBACONAZOLE

15.4.9 OTHER ANTIFUNGAL AGENTS:

15.4.9.1. CICLOPIROX

15.4.9.2. TAVABOROLE

15.4.9.3. EFINACONAZOLE

15.4.9.4. OTHER

15.5 ANTIPARASITIC DRUGS

15.5.1 ANTIMALARIAL DRUGS

15.5.1.1. CHLOROQUINE

15.5.1.2. ARTEMISININ AND ITS DERIVATIVES (ARTEMETHER, ARTESUNATE)

15.5.1.3. QUININE

15.5.1.4. MEFLOQUINE

15.5.1.5. ATOVAQUONE-PROGUANIL

15.5.1.6. PRIMAQUINE

15.5.1.7. DOXYCYCLINE

15.5.1.8. TAFENOQUINE

15.5.1.9. OTHER

15.5.2 ANTHELMINTICS

15.5.2.1. BENZIMIDAZOLES

15.5.2.1.1. ALBENDAZOLE

15.5.2.1.2. MEBENDAZOLE

15.5.2.1.3. OTHER

15.5.2.2. NICOTINIC AGONISTS

15.5.2.2.1. PYRANTEL PAMOATE

15.5.2.2.2. PYRVINIUM PAMOATE

15.5.2.2.3. OTHER

15.5.2.3. IVERMECTIN

15.5.2.4. PRAZIQUANTEL

15.5.2.5. DIETHYLCARBAMAZINE

15.5.2.6. OTHER

 

15.5.3 ANTIPROTOZOAL DRUGS

15.5.3.1. NITROIMIDAZOLES

15.5.3.1.1. METRONIDAZOLE

15.5.3.1.2. TINIDAZOLE

15.5.3.1.3. OTHER

15.5.3.2. QUINOLINES

15.5.3.2.1. CHLOROQUINE

15.5.3.2.2. HYDROXYCHLOROQUINE

15.5.3.2.3. OTHER

15.5.3.3. NITROFURANS

15.5.3.3.1. FURAZOLIDONE

15.5.4 PENTAMIDINE

15.5.5 ATOVAQUONE

15.5.6 OTHER

16 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY INDICATION

16.1 OVERVIEW

16.2 BACTERIAL INFECTIONS

16.2.1 PNEUMONIA

16.2.2 BRONCHITIS

16.2.3 SINUSITIS

16.2.4 CELLULITIS

16.2.5 WOUND INFECTIONS

16.2.6 GONORRHEA

16.2.7 SYPHILIS

16.2.8 CHLAMYDIA

16.2.9 PERITONITIS

16.2.10 DIVERTICULITIS

16.2.11 OSTEOMYELITIS

16.2.12 SEPTIC ARTHRITIS

16.2.13 BLOODSTREAM INFECTIONS (BACTEREMIA OR SEPSIS)

16.2.14 SURGICAL SITE INFECTIONS

16.2.15 MENINGITIS

16.2.16 DENTAL INFECTIONS

16.2.17 CONJUNCTIVITIS

16.2.18 KERATITIS

16.2.19 OTHER

 

16.3 VIRAL INFECTIONS

16.3.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION

16.3.2 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

16.3.3 INFLUENZA (FLU)

16.3.4 HERPES SIMPLEX VIRUS (HSV) INFECTIONS

16.3.5 VARICELLA-ZOSTER VIRUS (VZV) INFECTIONS

16.3.6 HEPATITIS B

16.3.7 HEPATITIS C

16.3.8 RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION

16.3.9 HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS

16.3.10 CYTOMEGALOVIRUS (CMV) INFECTIONS

16.3.11 OTHER

16.4 FUNGAL INFECTIONS

16.4.1 RAL THRUSH

16.4.2 VAGINAL YEAST INFECTION

16.4.3 RINGWORM

16.4.4 ATHLETE'S FOOT

16.4.5 CANDIDIASIS

16.4.6 ASPERGILLOSIS

16.4.7 CRYPTOCOCCAL MENINGITIS

16.4.8 OTHER

16.5 PARASITIC INFECTIONS

16.5.1 MALARIA

16.5.2 INTESTINAL WORM INFECTIONS

16.5.3 SCABIES

16.5.4 LICE INFESTATIONS

16.5.5 TOXOPLASMOSIS

16.5.6 TRYPANOSOMIASIS

16.5.7 LEISHMANIASIS

16.5.8 FILARIASIS (ELEPHANTIASIS)

16.5.9 OTHERS

 

17 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY DRUG TYPE

17.1 OVERVIEW

17.2 BRANDED

17.2.1 ANTIBIOTICS

17.2.1.1. AMOXIL

17.2.1.2. ZITHROMAX

17.2.1.3. CIPRO

17.2.1.4. BIAXIN

17.2.1.5. CLEOCIN

17.2.1.6. OTHER

17.2.2 ANTIVIRAL

17.2.2.1. TAMIFLU

17.2.2.2. RELENZA

17.2.2.3. ZOVIRAX

17.2.2.4. VALTREX

17.2.2.5. FAMVIR

17.2.2.6. CYTOVENE

17.2.2.7. COPEGUS

17.2.2.8. SOVALDI

17.2.2.9. HARVONI

17.2.2.10. VEKLURY

17.2.2.11. OTHER

17.2.3 ANTIFUNGAL

17.2.3.1. SPORANOX

17.2.3.2. DIFLUCAN

17.2.3.3. VFEND

17.2.3.4. NOXAFIL

17.2.3.5. NIZORAL

17.2.3.6. FUNGIZONE

17.2.3.7. MYCOSTATIN

17.2.3.8. OTHER

17.2.4 ANTIPARASITIC DRUGS

17.2.4.1. ARALEN

17.2.4.2. LARIAM

17.2.4.3. STROMECTOL

17.2.4.4. ALBENZA

17.2.4.5. BILTRICIDE

17.2.4.6. MALARONE

17.2.4.7. FLAGYL

17.2.4.8. OTHER

17.3 GENERICS

18 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY MODE OF PURCHASE

18.1 OVERVIEW

18.2 PRESCRIPTION

18.3 OVER THE COUNTER

19 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY ROUTE OF ADMINISTRATION

19.1 OVERVIEW

19.2 ORAL

19.2.1 TABLET

19.2.2 CAPSULE

19.2.3 LIQUID

19.2.4 OTHER

19.3 PARENTERAL

19.3.1 INTRAMUSCULARLY

19.3.2 SUBCUTANEOUSLY

19.3.3 INTRAVENOUS

19.4 TOPICAL

19.4.1 CREAMS

19.4.2 OINTMENTS

19.4.3 POWDERS

19.4.4 SPRAYS

19.5 INTRAVAGINAL

19.6 RECTAL

19.7 OTHER

20 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY PATIENT TYPE

20.1 OVERVIEW

20.2 PEDIATRIC

20.3 ADULT

20.3.1 MALE

20.3.2 FEMALE

20.4 GERIATRIC

20.4.1 MALE

20.4.2 FEMALE

 

21 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY END USER

21.1 OVERVIEW

21.2 HOSPITAL & CLINICS

21.2.1 PUBLIC

21.2.2 PRIVATE

21.3 SPECIALTY CENTRES

21.4 AMBULATORYSURGICAL CENTER

21.5 TRAUMA CENTERS

21.6 HOME HEALTHCARE

21.7 OTHERS

22 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL

22.1 OVERVIEW

22.2 DIRECT TENDER

22.3 RETAIL PAHRMACIES

22.3.1 HOSPITAL ASSOCIATED PHARMACY

22.3.2 RETAIL PHARMACY

22.3.3 ONLINE PHARMACY

22.3.4 OTHER

22.4 OTHERS

23 GLOBAL ANTI-INFECTIVE DRUGS MARKET, COMPANY LANDSCAPE

23.1 COMPANY SHARE ANALYSIS: GLOBAL

23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

23.3 COMPANY SHARE ANALYSIS: EUROPE

23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

23.5 MERGERS & ACQUISITIONS

23.6 NEW PRODUCT DEVELOPMENT & APPROVALS

23.7 EXPANSIONS

23.8 REGULATORY CHANGES

23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

 

24 GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY GEOGRAPHY

GLOBAL ANTI-INFECTIVE DRUGS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

24.1 NORTH AMERICA

24.1.1 U.S.

24.1.2 CANADA

24.1.3 MEXICO

24.2 EUROPE

24.2.1 GERMANY

24.2.2 U.K.

24.2.3 ITALY

24.2.4 FRANCE

24.2.5 SPAIN

24.2.6 RUSSIA

24.2.7 SWITZERLAND

24.2.8 TURKEY

24.2.9 BELGIUM

24.2.10 NETHERLANDS

24.2.11 DENMARK

24.2.12 SWEDEN

24.2.13 POLAND

24.2.14 NORWAY

24.2.15 FINLAND

24.2.16 REST OF EUROPE

24.3 ASIA-PACIFIC

24.3.1 JAPAN

24.3.2 CHINA

24.3.3 SOUTH KOREA

24.3.4 INDIA

24.3.5 SINGAPORE

24.3.6 THAILAND

24.3.7 INDONESIA

24.3.8 MALAYSIA

24.3.9 PHILIPPINES

24.3.10 AUSTRALIA

24.3.11 NEW ZEALAND

24.3.12 VIETNAM

24.3.13 TAIWAN

24.3.14 REST OF ASIA-PACIFIC

 

24.4 SOUTH AMERICA

24.4.1 BRAZIL

24.4.2 ARGENTINA

24.4.3 PERU

24.4.4 REST OF SOUTH AMERICA

24.5 MIDDLE EAST AND AFRICA

24.5.1 SOUTH AFRICA

24.5.2 EGYPT

24.5.3 BAHRAIN

24.5.4 UNITED ARAB EMIRATES

24.5.5 KUWAIT

24.5.6 OMAN

24.5.7 QATAR

24.5.8 SAUDI ARABIA

24.5.9 REST OF MEA

24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

25 GLOBAL ANTI-INFECTIVE DRUGS MARKET, SWOT AND DBMR ANALYSIS

26 GLOBAL ANTI-INFECTIVE DRUGS MARKET, COMPANY PROFILE

26.1 JOHNSONS & JOHNSONS SERVICES INC

26.1.1 COMPANY OVERVIEW

26.1.2 REVENUE ANALYSIS

26.1.3 GEOGRAPHIC PRESENCE

26.1.4 PRODUCT PORTFOLIO

26.1.5 RECENT DEVELOPEMNTS

26.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

26.2.1 COMPANY OVERVIEW

26.2.2 REVENUE ANALYSIS

26.2.3 GEOGRAPHIC PRESENCE

26.2.4 PRODUCT PORTFOLIO

26.2.5 RECENT DEVELOPEMNTS

26.3 ABBVIE, INC

26.3.1 COMPANY OVERVIEW

26.3.2 REVENUE ANALYSIS

26.3.3 GEOGRAPHIC PRESENCE

26.3.4 PRODUCT PORTFOLIO

26.3.5 RECENT DEVELOPEMNTS

 

26.4 SUN PHARMACEUTICAL INDUSTRIES LTD.

26.4.1 COMPANY OVERVIEW

26.4.2 REVENUE ANALYSIS

26.4.3 GEOGRAPHIC PRESENCE

26.4.4 PRODUCT PORTFOLIO

26.4.5 RECENT DEVELOPEMNTS

26.5 SANOFI

26.5.1 COMPANY OVERVIEW

26.5.2 REVENUE ANALYSIS

26.5.3 GEOGRAPHIC PRESENCE

26.5.4 PRODUCT PORTFOLIO

26.5.5 RECENT DEVELOPEMNTS

26.6 GSK PLC.

26.6.1 COMPANY OVERVIEW

26.6.2 REVENUE ANALYSIS

26.6.3 GEOGRAPHIC PRESENCE

26.6.4 PRODUCT PORTFOLIO

26.6.5 RECENT DEVELOPEMNTS

26.7 NOVARTIS AG

26.7.1 COMPANY OVERVIEW

26.7.2 REVENUE ANALYSIS

26.7.3 GEOGRAPHIC PRESENCE

26.7.4 PRODUCT PORTFOLIO

26.7.5 RECENT DEVELOPEMNTS

26.8 PFIZER INC.

26.8.1 COMPANY OVERVIEW

26.8.2 REVENUE ANALYSIS

26.8.3 GEOGRAPHIC PRESENCE

26.8.4 PRODUCT PORTFOLIO

26.8.5 RECENT DEVELOPEMNTS

26.9 HIKMA PHARMACEUTICALS PLC

26.9.1 COMPANY OVERVIEW

26.9.2 REVENUE ANALYSIS

26.9.3 GEOGRAPHIC PRESENCE

26.9.4 PRODUCT PORTFOLIO

26.9.5 RECENT DEVELOPEMNTS

 

26.1 AMNEAL PHARMACEUTICALS LLC.

26.10.1 COMPANY OVERVIEW

26.10.2 REVENUE ANALYSIS

26.10.3 GEOGRAPHIC PRESENCE

26.10.4 PRODUCT PORTFOLIO

26.10.5 RECENT DEVELOPEMNTS

26.11 ALEMBIC PHARMACEUTICALS LIMITED

26.11.1 COMPANY OVERVIEW

26.11.2 REVENUE ANALYSIS

26.11.3 GEOGRAPHIC PRESENCE

26.11.4 PRODUCT PORTFOLIO

26.11.5 RECENT DEVELOPEMNTS

26.12 ZYDUS GROUP

26.12.1 COMPANY OVERVIEW

26.12.2 REVENUE ANALYSIS

26.12.3 GEOGRAPHIC PRESENCE

26.12.4 PRODUCT PORTFOLIO

26.12.5 RECENT DEVELOPEMNTS

26.13 FRESENIUS KABI

26.13.1 COMPANY OVERVIEW

26.13.2 REVENUE ANALYSIS

26.13.3 GEOGRAPHIC PRESENCE

26.13.4 PRODUCT PORTFOLIO

26.13.5 RECENT DEVELOPEMNTS

26.14 MERCK & CO., INC.

26.14.1 COMPANY OVERVIEW

26.14.2 REVENUE ANALYSIS

26.14.3 GEOGRAPHIC PRESENCE

26.14.4 PRODUCT PORTFOLIO

26.14.5 RECENT DEVELOPEMNTS

26.15 ROCHE HOLDING AG

26.15.1 COMPANY OVERVIEW

26.15.2 REVENUE ANALYSIS

26.15.3 GEOGRAPHIC PRESENCE

26.15.4 PRODUCT PORTFOLIO

26.15.5 RECENT DEVELOPEMNTS

 

26.16 ASTRAZENECA PLC

26.16.1 COMPANY OVERVIEW

26.16.2 REVENUE ANALYSIS

26.16.3 GEOGRAPHIC PRESENCE

26.16.4 PRODUCT PORTFOLIO

26.16.5 RECENT DEVELOPEMNTS

26.17 BAYER AG

26.17.1 COMPANY OVERVIEW

26.17.2 REVENUE ANALYSIS

26.17.3 GEOGRAPHIC PRESENCE

26.17.4 PRODUCT PORTFOLIO

26.17.5 RECENT DEVELOPEMNTS

26.18 ELI LILLY AND COMPANY

26.18.1 COMPANY OVERVIEW

26.18.2 REVENUE ANALYSIS

26.18.3 GEOGRAPHIC PRESENCE

26.18.4 PRODUCT PORTFOLIO

26.18.5 RECENT DEVELOPEMNTS

26.19 GILEAD SCIENCES, INC.

26.19.1 COMPANY OVERVIEW

26.19.2 REVENUE ANALYSIS

26.19.3 GEOGRAPHIC PRESENCE

26.19.4 PRODUCT PORTFOLIO

26.19.5 RECENT DEVELOPEMNTS

26.2 BRISTOL MYERS SQUIBB COMPANY

26.20.1 COMPANY OVERVIEW

26.20.2 REVENUE ANALYSIS

26.20.3 GEOGRAPHIC PRESENCE

26.20.4 PRODUCT PORTFOLIO

26.20.5 RECENT DEVELOPEMNTS

26.21 ASTELLAS PHARMA INC.

26.21.1 COMPANY OVERVIEW

26.21.2 REVENUE ANALYSIS

26.21.3 GEOGRAPHIC PRESENCE

26.21.4 PRODUCT PORTFOLIO

26.21.5 RECENT DEVELOPEMNTS

 

26.22 TAKEDA PHARMACEUTICAL COMPANY LIMITED

26.22.1 COMPANY OVERVIEW

26.22.2 REVENUE ANALYSIS

26.22.3 GEOGRAPHIC PRESENCE

26.22.4 PRODUCT PORTFOLIO

26.22.5 RECENT DEVELOPEMNTS

26.23 CIPLA LTD

26.23.1 COMPANY OVERVIEW

26.23.2 REVENUE ANALYSIS

26.23.3 GEOGRAPHIC PRESENCE

26.23.4 PRODUCT PORTFOLIO

26.23.5 RECENT DEVELOPEMNTS

26.24 LUPIN

26.24.1 COMPANY OVERVIEW

26.24.2 REVENUE ANALYSIS

26.24.3 GEOGRAPHIC PRESENCE

26.24.4 PRODUCT PORTFOLIO

26.24.5 RECENT DEVELOPEMNTS

26.25 GLENMARK PHARMACEUTICALS LTD.

26.25.1 COMPANY OVERVIEW

26.25.2 REVENUE ANALYSIS

26.25.3 GEOGRAPHIC PRESENCE

26.25.4 PRODUCT PORTFOLIO

26.25.5 RECENT DEVELOPEMNTS

26.26 DR. REDDY'S LABORATORIES LTD.

26.26.1 COMPANY OVERVIEW

26.26.2 REVENUE ANALYSIS

26.26.3 GEOGRAPHIC PRESENCE

26.26.4 PRODUCT PORTFOLIO

26.26.5 RECENT DEVELOPEMNTS

26.27 REGENERON PHARMACEUTICALS, INC.

26.27.1 COMPANY OVERVIEW

26.27.2 REVENUE ANALYSIS

26.27.3 GEOGRAPHIC PRESENCE

26.27.4 PRODUCT PORTFOLIO

26.27.5 RECENT DEVELOPEMNTS

 

26.28 JIANGSU HENGRUI MEDICINE CO., LTD.

26.28.1 COMPANY OVERVIEW

26.28.2 REVENUE ANALYSIS

26.28.3 GEOGRAPHIC PRESENCE

26.28.4 PRODUCT PORTFOLIO

26.28.5 RECENT DEVELOPEMNTS

26.29 GENETECH

26.29.1 COMPANY OVERVIEW

26.29.2 REVENUE ANALYSIS

26.29.3 GEOGRAPHIC PRESENCE

26.29.4 PRODUCT PORTFOLIO

26.29.5 RECENT DEVELOPEMNTS

26.3 HETERO

26.30.1 COMPANY OVERVIEW

26.30.2 REVENUE ANALYSIS

26.30.3 GEOGRAPHIC PRESENCE

26.30.4 PRODUCT PORTFOLIO

26.30.5 RECENT DEVELOPEMNTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

27 RELATED REPORTS

28 CONCLUSION

29 QUESTIONNAIRE

30 ABOUT DATA BRIDGE MARKET RESEARCH